Teva Pharmaceuticals
TEVA
821 hedge funds and large institutions have $32.5B invested in Teva Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 281 increasing their positions, 297 reducing their positions, and 70 closing their positions.
89% more call options, than puts
Call options by funds: $780M | Put options by funds: $412M
19% more funds holding in top 10
Funds holding in top 10: 59 → 70 (+11)
11% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 70
5% more capital invested
Capital invested by funds: $31.1B → $32.5B (+$1.45B)
0% more funds holding
Funds holding: 821 → 821 (0)
0.28% less ownership
Funds ownership: 54.89% → 54.6% (-0.28%)
5% less repeat investments, than reductions
Existing positions increased: 281 | Existing positions reduced: 297
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$525M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$247M |
| 3 |
Millennium Management
New York
|
+$215M |
| 4 |
PC
PointState Capital
New York
|
+$129M |
| 5 |
First Eagle Investment Management
New York
|
+$102M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Americafirst Capital Management
Roseville,
California
|
-$916M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$904M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$394M |
| 4 |
CG
Carmignac Gestion
Paris,
France
|
-$352M |
| 5 |
SFM
Soros Fund Management
New York
|
-$279M |
TEVA Hedge Fund Activity: Q1 2015 in Review
821 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2015, worth a combined $32.5B — up 4.7% from $31.1B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new TEVA positions and 70 closed out — a net gain of 8 holders — while 281 added to existing stakes and 297 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $525M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $916M sold.
- 821 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $32.5B of Teva Pharmaceuticals stock for Q1 2015, up 4.7% quarter-over-quarter.
- 78 funds opened new Teva Pharmaceuticals positions in Q1 2015 and 70 closed out, a net change of +8 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2015 was Fidelity Investments, an estimated $525M added.
- The largest Teva Pharmaceuticals seller in Q1 2015 was Americafirst Capital Management, an estimated $916M sold.
Based on aggregated 13F filings for Q1 2015.